The study involves patients with Multiple Myeloma, a cancer of the bone‑marrow cells that produce blood cells. Some of these patients have already received a type of advanced treatment called CAR T-cell therapy, which uses the patient’s own immune cells that have been altered to attack the cancer. The new treatment being tested combines three medicines: cevostamab, which is given by a drip into a vein (intravenous infusion); pomalidomide, which is taken as a pill by mouth (oral); and dexamethasone, which is also given through a vein.
The purpose of the study is to see how well this combination works and how safe it is for people whose disease has come back after previous therapy. Participants will receive the medicines on a regular schedule, attend clinic visits for check‑ups, have blood drawn, and may have other simple tests to monitor how the disease is responding and to watch for any side effects.
The study continues for several months, during which doctors will look for any improvement in the cancer, record any problems that arise, and follow participants after treatment ends to see how long any benefit lasts.
Germany 
